ClinicalTrials.gg
CompletedNCT05285982Updated Mar 4, 2026Results posted

A Study to Evaluate Long-term Safety of Nintedanib in Children and Adolescents With Interstitial Lung Disease (InPedILD®-ON)

A Phase 3 interventional study of Nintedanib (Ofev®) in Lung Diseases, Interstitial, sponsored by Boehringer Ingelheim. Completed at 28 sites in 17 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-03-04.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
54
Allocation
Not applicable
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing nintedanib in Lung Diseases, Interstitial — 1 open to participants now, 1 under way, 1 of them phase 3. nintedanib · Lung Diseases, Interstitial.

Enrollment
8th of 11
54 · median 81
Started
2022
the only one that year
Phase 3
8 of 11
1 open now
Registered
8th of 11
by date
Lead sponsor
6 of 11
Boehringer Ingelheim

Among the 11 studies testing nintedanib in Lung Diseases, Interstitial, this one is the 8th largest by enrollment, is the only one that started in 2022, is one of 8 in phase 3, and was the 8th registered.

Lung Diseases, Interstitial

682 studies on the registry are indexed under Lung Diseases, Interstitial; 246 are open to participants now.

Browse Lung Diseases, Interstitial studies →

Open to participants now

1 of the 11 studies testing nintedanib in Lung Diseases, Interstitial is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About nintedanib

nintedanib: first FDA approval 2014 (OFEV), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Lung Diseases, Interstitial studies recruiting now, 108 (62%) set no upper age limit and 25 (14%) stop at 75 or younger; 13 take children under 18; 21 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing nintedanib in Lung Diseases, Interstitial, or all of them as a file.
02

Study summary

This study is open to children and adolescents with interstitial lung disease (ILD) that causes lung fibrosis. This is a study for people who took part in a previous study called InPedILD (study 1199-0337) and for people who are between 6 and 17 years old (in France, between 12 and 17 years old) and have fibrosing ILD.

This study tests a medicine called nintedanib. Nintedanib is already used to treat different types of lung fibrosis in adults. The purpose of the study is to find out how well long-term treatment with nintedanib is tolerated in children and adolescents.

All participants take nintedanib capsules twice a day. Participants coming from the previous study are in this study for at least 3 years or until nintedanib or other treatment options become available outside of this study. New participants are in the study until the overall end of study meaning for at least 1.5 years. Participants visit the study site about 15 times for a study participation of 3 years. Afterwards, they visit the study site every 3 months. The doctors collect information on any health problems of the participants.

03

Conditions studied

  • Lung Diseases, Interstitial
04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For new patients:

  1. Children and adolescents 6 to 17 years old at Visit 2. In France, only adolescents 12 to 17 years old at Visit 2.
  2. Signed and dated written and assent, where applicable, in accordance with ICH-GCP and local legislation prior to admission to the trial.
  3. Male or female patients. Female of (WOCBP1) must confirm that sexual abstinence is standard practice and will be continued until 3 months after last drug intake, or be ready and able to use a highly effective method of per ICH M3 (R2) that results in a low failure rate of less than 1% per year when used consistently and correctly, in combination with one barrier method, from 28 days prior to initiation of study treatment, during treatment and until 3 months after last drug intake. Sexual abstinence is defined as abstinence from any sexual act that may result in pregnancy.
  4. Patients with evidence of fibrosing Interstitial Lung Disease (ILD) on High-Resolution Computed Tomography (HRCT) within 12 months of Visit 1 as assessed by the investigator and confirmed by central review.
  5. Patients with Forced Vital Capacity (FVC) % predicted ≥25% at Visit 2.
  6. Patients with disease at Visit 2, as assessed by the investigator based on any of the following:

    • Fan score ≥3, or
    • Documented evidence of clinical progression over time based on either

      • a 5-10% relative decline in FVC % predicted accompanied by worsening symptoms, or
      • a ≥10% relative decline in FVC % predicted, or
      • increased fibrosis on HRCT, or
      • other measures of clinical worsening attributed to progressive lung disease (e.g. increased oxygen requirement, decreased diffusion capacity).

    For roll-over patients from the InPedILD® study:

    Only criteria 2 and 3 listed for new patients are applicable with the following additional inclusion criterion:

  7. Patients who completed the InPedILD® trial as planned and who did not permanently prematurely discontinue study treatment.

For patients who prematurely discontinued treatment permanently in 1199-0337 but are potentially eligible and for completed patients from parent trial not able to roll over into the extension trial within 12 weeks following their End of Treatment Visit in the parent trial:

Inclusion criteria for new patients are applicable except criteria 4, and 6 (as eligibility for these criteria has been confirmed already in 1199-0337 and does not need to be repeated) and also except inclusion criterion 1 for completed patients from parent trial not able to roll over within 12 weeks following their End of Treatment Visit in the parent trial.

Exclusion criteria

Exclusion Criteria:

For new patients:

  1. (AST) and/or Alanine Aminotransferase (ALT) >1.5 x (ULN) at Visit 1.
  2. >1.5 x ULN at Visit 1.
  3. Estimated (eGFR) \<30 mL/min/1.73 m² at Visit 1
  4. Patients with underlying chronic liver disease ( A, B or C hepatic impairment) at Visit 1.
  5. Other therapy received within 1 month or 5 half-lives (whichever is shorter but ≥1 week) prior to Visit 2 except investigational therapy received in InPedILD® trial.
  6. Significant pulmonary arterial hypertension (PAH) defined by any of the following:

    • Previous clinical or echocardiographic evidence of significant right heart failure
    • History of right heart catheterization showing a cardiac index ≤2 l/min/m²
    • PAH requiring parenteral therapy with epoprostenol/treprostinil
  7. In the opinion of the Investigator, other pulmonary abnormalities.
  8. Cardiovascular diseases, any of the following:

    • Severe hypertension, uncontrolled under treatment, within 6 months of Visit 1. Uncontrolled hypertension is defined as

      • In children 6 to ≤12 years old: ≥95th percentile + 12 mm Hg or ≥140/90 mm Hg (whichever is lower) (systolic or diastolic blood pressure equal to or greater than the calculated target value). Not applicable in France.
      • In adolescents 13 to 17 years old: systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg. Not applicable in France.
    • Myocardial infarction within 6 months of Visit 1
    • Unstable cardiac angina within 6 months of Visit 1
  9. Bleeding risk, any of the following:

    • Known genetic predisposition to bleeding
    • Patients who require

      • Fibrinolysis, full-dose therapeutic anticoagulation (e.g. vitamin K antagonists, direct thrombin inhibitors, heparin, hirudin)
      • High dose antiplatelet therapy
    • History of haemorrhagic central nervous system (CNS) event within 12 months of Visit 1
    • Any of the following within 3 months of Visit 1:

      • Haemoptysis or haematuria
      • Active gastro-intestinal (GI) bleeding or GI - ulcers
      • Major injury or surgery (investigator's judgment)
    • Any of the following coagulation parameters at Visit 1:

      • (INR) >2
      • Prolongation of prothrombin time (PT) by >1.5 x ULN
      • Prolongation of activated partial thromboplastin time (aPTT) by >1.5 x ULN
  10. History of thrombotic event (including stroke and ) within 12 months of Visit 1.
  11. Known to the trial medication or its components (i.e. soya lecithin).
  12. Patients with documented allergy to peanut or soya.
  13. Other disease that may interfere with testing procedures or in the judgment of the investigator may interfere with trial participation or may put the patient at risk when participating in this trial.
  14. for any concomitant disease other than ILD \<2.5 years (investigator assessment).
  15. Female patients who are pregnant, nursing, or who plan to become pregnant while in the trial.
  16. Patients not able or willing to adhere to trial procedures, including intake of study medication.
  17. Patients who must or wish to take any drug considered likely to interfere with the safe conduct of the trial according to investigator's benefit-risk assessment for the individual patient
  18. Patients with any diagnosed growth disorder such as growth hormone deficiency or any genetic disorder that is associated with short stature (e.g. Turner Syndrome, Noonan Syndrome, Russell-Silver Syndrome) and/or treatment with growth hormone therapy within 6 months before Visit 2. Patients with short stature considered by the investigator to be due to therapy may be included.
  19. Patients \<13.5 kg of weight at Visit 1 (same threshold to be used for male and female patients).

    For roll-over patients from the InPedILD® study:

    Only criteria 11, 12, 13, 15, 16, 17 and 19, listed for new patients are applicable with the following additional exclusion criterion:

  20. Patient not compliant in parent trial (InPedILD®), with trial medication or trial visits, according to investigator's judgement. Roll-over patients may qualify for participation even though other exclusion criteria may have been met during the participation in InPedILD®, if the investigator's benefit-risk assessment for the individual patient remains favorable.

    For patients who prematurely discontinued treatment permanently in 1199-0337 but are potentially eligible and for completed patients from parent trial not able to roll over into the extension trial within 12 weeks following their End of Treatment Visit in the parent trial:

    All exclusion criteria for new patients are applicable. In addition, the following additional exclusion criterion is applicable for patients who prematurely discontinued treatment permanently in 1199-0337:

  21. Patients who experienced drug-related adverse events during parent trial leading to permanent study treatment discontinuation.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    Nintedanib

    Pediatric patients with clinically significant fibrosing intestitial lung disease (ILD) who either completed the parent trial 1199-0337 or were new patients received nintedanib soft gelatine capsules. Nintedanib doses ranged from 50 milligrams (mg) bid (13.5 to \< 23 kilograms (kg) bodyweight) to 150 mg bid (\>=57.5 kg bodyweight).

    Drug: Nintedanib (Ofev®)

Interventions

  • Nintedanib soft capsules administered orally with doses ranged from 50 to 150 mg bid depending on body weight

    Also known as: Ofev

06

What researchers measure

Primary outcomes

  1. Number of Patients With Treatment-emergent Adverse Events (AEs) Over the Whole Trial

    Number of patients with treatment-emergent adverse events (AEs) over the whole trial.

    Time frame: From first drug administration until end of residual effect period (REP) 28 days after the last dose of trial medication, up to 1127 days.

07

Results

Posted Mar 4, 2026
Limitations and caveats
Some limitations due to the nature of the extension trial should be considered when interpreting the data (i.e. bias in the selection of the population and no comparative arm). All endpoints were considered exploratory only.

Participant flow

Pediatric patients with clinically significant fibrosing Interstitial Lung Disease who completed the parent trial 1199-0337 or new patients who were eligible to enter this trial.

Participant flow — Overall Study
MilestoneNintedanib
Started54
Completed30
Not completed24
Withdrew: Adverse event7
Withdrew: Burden of trial procedures2
Withdrew: Other treatment option available2
Withdrew: Perceived lack of efficacy2
Withdrew: Change of residence1
Withdrew: No reason provided1
Withdrew: Other than listed9

Outcome measures

PrimaryNumber of Patients With Treatment-emergent Adverse Events (AEs) Over the Whole Trial

Number of patients with treatment-emergent adverse events (AEs) over the whole trial.

Time frame:
From first drug administration until end of residual effect period (REP) 28 days after the last dose of trial medication, up to 1127 days.
Reported as:
Count of participants · Participants
Number of Patients With Treatment-emergent Adverse Events (AEs) Over the Whole Trial
ParticipantsNintedanib
Number of Patients With Treatment-emergent Adverse Events (AEs) Over the Whole Trial53

Adverse events

Collected over From first drug administration until end of residual effect period (REP) 28 days after the last dose of trial medication, up to 1127 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nintedanib3/54 (5.6%)24/54 (44.4%)53/54 (98.1%)
Most frequent serious events
Showing 10 of 36
Most frequent serious events
EventNintedanib
Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders4/54
Respiratory tract infectionInfections and infestations2/54
HeadacheNervous system disorders2/54
DyspnoeaRespiratory, thoracic and mediastinal disorders2/54
PneumothoraxRespiratory, thoracic and mediastinal disorders2/54
Respiratory failureRespiratory, thoracic and mediastinal disorders2/54
Sickle cell anaemia with crisisBlood and lymphatic system disorders1/54
Atrial thrombosisCardiac disorders1/54
Right ventricular failureCardiac disorders1/54
Sickle cell anaemiaCongenital, familial and genetic disorders1/54
Most frequent other events
Showing 10 of 40
Most frequent other events
EventNintedanib
DiarrhoeaGastrointestinal disorders26/54
VomitingGastrointestinal disorders21/54
NauseaGastrointestinal disorders17/54
Dental cariesGastrointestinal disorders16/54
CoughRespiratory, thoracic and mediastinal disorders16/54
HeadacheNervous system disorders13/54
Upper respiratory tract infectionInfections and infestations12/54
NasopharyngitisInfections and infestations11/54
Abdominal painGastrointestinal disorders10/54
Respiratory tract infectionInfections and infestations9/54

Baseline characteristics

Treated Set (TS): The TS included all patients who were administered at least 1 dose of trial medication.

Age, Continuous
Age, Continuous(years)Nintedanib
Mean13.6 ± 3.3
Sex: Female, Male
Sex: Female, Male(Participants)Nintedanib
Female33
Male21
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Nintedanib
Hispanic or Latino16
Not Hispanic or Latino37
Unknown or Not Reported1
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Nintedanib
American Indian or Alaska Native3
Asian2
Native Hawaiian or Other Pacific Islander0
Black or African American6
White41
More than one race1
Unknown or Not Reported1
08

Study locations

28 sites
  • Children's Hospital Los Angeles
    Los Angeles, California 90027, United States
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • Weill Cornell Medicine-New York-60569
    New York, New York 10021, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15224, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • Hospital de Pediatria Prof. Dr. Juan P. Garrahan
    CABA, C1245AAM, Argentina
  • Hospital de Niños Dr. Ricardo Gutierrez
    CABA, C1425EFD, Argentina
  • Brussels - UNIV HUDERF
    Brussels, 1020, Belgium
  • Serviços Medicos Respirar Sul Fluminense
    Barra Mansa, 27323240, Brazil
  • Centro de Pesquisa Clinica do Instituto da Crianca - HCFMUSP
    São Paulo, 5403-900, Brazil
  • BC Children's Hospital
    Vancouver, British Columbia V6H 3N1, Canada
  • The Hospital for Sick Children
    Toronto, Ontario M5G 1X8, Canada
  • Teaching Hospital Motol, Oncology Clinic
    Prague, 150 06, Czechia
  • Tampere University Hospital
    Tampere, 33520, Finland
  • HOP Intercommunal
    Créteil, 94010, France
  • Hamburger Zentrum für Kinder- und Jugendrheumatologie
    Hamburg, 22081, Germany
  • General Hospital of Thessaloniki "Ippokrateio"
    Thessaloniki, 54642, Greece
  • Azienda Ospedaliera Meyer
    Florence, 50139, Italy
  • Osp. Pediatrico Bambin Gesù
    Roma, 00165, Italy
  • Clinical Research Institute S.C.
    Tlalnepantla, 54055, Mexico
  • Oslo Universitetssykehus HF, Rikshospitalet
    Oslo, N-0372, Norway
  • Independent Public Teaching Children's Hospital
    Warsaw, 02091, Poland
  • ULS de São José, E.P.E. - Hospital Dona Estefânia
    Lisbon, 1169-045, Portugal
  • ULS de Santa Maria, E.P.E
    Lisbon, 1649-035, Portugal
  • Hospital Universitari Vall D Hebron
    Barcelona, 08035, Spain
  • Hospital Virgen del Rocío
    Seville, 41013, Spain
  • King's College Hospital
    London, SE5 9RS, United Kingdom
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Once the criteria in section "Time Frame" are fulfilled, researchers can use the following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: After structured results have been posted, all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.

Access criteria: For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.

Data sharing details ↗ · www.mystudywindow.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2022 to primary completion in Aug 2025, 40 months.

Results were first posted in Mar 2026, 6 months after primary completion.

Of 36 phase 3 interventional studies under Lung Diseases, Interstitial, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 61. This study's 40 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2022
First posted
Mar 18, 2022
StartActual
Apr 6, 2022
Primary completionActual
Aug 13, 2025
CompletionActual
Aug 13, 2025
Results first posted
Mar 4, 2026
Last update
Mar 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05285982
Responsible party
Sponsor
First posted
Mar 18, 2022
Start date
Apr 6, 2022
Primary completion
Aug 13, 2025
Completion
Aug 13, 2025
Results posted
Mar 4, 2026
Last update
Mar 4, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nintedanib

Start the discussion